Topics of the MipTec Conference 2010
Program Chairs:
Johannes Mosbacher, Actelion Pharmaceuticals Ltd., Allschwil, CH
William Janzen, University of North Carolina, Chapel Hill, USA
Poster Chairs:
Anna Seelig, Biozentrum Basel, Basel, CH
Nicolas Winssinger, Strasbourg University, Strasbourg, FR
Drug Discovery Technologies
Academic Screening
Chairs:
Hubert Haag, Sanofi-Aventis Pharma, Frankfurt, DE
Marc Bickle, Max-Planck-Institute, Dresden, DE
Lab Automation and Informatics
Chairs:
Sabrina Corazza, Axxam, Milan, IT
Niklaus Graber, Novartis Pharma AG, Basel, CH
High Content Screening
Chairs:
Daniela Gabriel, Novartis, Basel, CH
Renate Schnitzer, Boehringer-Ingelheim, Vienna, AT
Future Technologies for the Study of Biological Interactions
Chairs:
Al Kolb, KeyTech, Madison, USA
Gregor Dernick, F. Hoffmann-La Roche, Basel, CH
Description:
Recent trends and innovative enabling technologies in the areas of “Academic Screening”, “Lab Automation and Informatics”, “High Content Screening” and “Future Technologies for the Study of Biological Interactions”.
Target and Tools
Neglected Diseases
Chairs:
Dominique Besson, WHO, Geneva, CH
Michael Entzeroth, Experimental Therapeutics Centre, Singapore, SG
Epigenetics
Chairs:
William Janzen, University of North Carolina, Chapell Hill, USA
Chas Bountra, Oxford University, Oxford, UK
Protein Protein Interactions
Chairs:
Kurt Amrein, F. Hoffmann-La Roche, Basel, CH
Emilio Diez, GlaxoSmithKline S.A., Madrid, ES
RNAi and microRNAs
Chairs:
Ekkehard Leberer, Sanofi-Aventis Pharma, Frankfurt, DE
Helge Grosshans, Friedrich Miescher Institute, Basel, C
Description:
State-of-the-art basic and applied research including “Neglected Diseases”, “Epigenetics”, “Protein-Protein Interactions” and “RNAi and microRNAs”.
Chemical Space
Chairs:
John Harris, BioFocusDPI, Cambridge, UK
Nicolas Winssinger, Strasbourg University, FR
Christopher Lipinski, Melior Discovery, Waterford, USA
Description:
The Chemical Space Sessions in MipTec 2010 follow the very successful format first introduced in MipTec 2009. In this year’s MipTec there are three sub-sessions each consisting of three speakers who are experts in some aspect of maximizing the value to be found in chemistry space.
The three speakers in the Wednesday afternoon September 22 sub-session will explore the Nature of Chemical Space from bioinformatic, cell signaling and structural biology perspectives. The three speakers in the first Friday morning September 24 sub-session will explore the value of chemistry space to be found in Protein-Protein Interaction modulators. This session on the design and end results of modulating protein-protein interactions complements the focus on the technology of protein-protein interaction screening in the tools and technology session the day earlier on Thursday morning September 23. The three speakers in the second Friday morning September 24 sub-session will explore the value of chemistry space to be found in Fragment Screening.
Structural and Computational Drug Discovery
Chairs:
Alexander Hillisch, Bayer-Schering, Wuppertal, DE
Michael Sundström, NNF Center, Copenhagen, DK
Description:
Novel experimental and computational approaches in the areas of “Structural Chemical Biology” and “Structure-based Lead Selection and Optimization”.
Biopharmaceuticals
Chairs:
Stefan Ewert, Novartis, Basel, CH
Frank Fan, Promega Corporation, Madison, USA
Sandra Turconi, Ablynx, Ghent, BE
Description:
Following the successful introduction last year, MipTec is expanding the scope of the session dedicated to Biopharmaceutical drug discovery. This year, a wider range of topics will be covered, spanning the areas of Research, Pre-Clinical and Clinical Development. The aim of the session is to give a comprehensive insight into the main current issues in this branch of the Pharmaceutical industry.
This session will consist of two parts, dedicated to Research and Development topics respectively. Research topics will span the process of lead identification, characterization and/or optimization while the Development topics will deal with immunogenicity, delivery routes and regulatory aspects. It is hoped that the session will serve both as an introduction to the scientist working in the “small molecules” area as well as offering a discussion platform to the experienced practitioners in the biopharmaceuticals arena.
Translational Science
Chairs:
Peter McLean, Nestlé, Lausanne, CH
Peter Berndt, F. Hoffmann-La Roche, Basel, CH
Salvatore Alesci, Pfizer, Philadelphia, USA
Description:
Translation of basic research into therapies based on biomarkers, imaging approaches, and state-of-the art diagnostic technologies. Case studies and reviews in several indication areas will highlight how to bridge the gap between basic research in the lab and proof-of-concept (PoC) in man. Public-private partnerships in this area are becoming of ever increasing importance in today’s R&D at Pharma & Biotech.
